Advertisement
RedHill Says Its Oral Antivirals, Opaganib And RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
(RTTNews) - Specialty biopharmaceutical company RedHill Biopharma Ltd. (RDHL) announced Monday the study results showing in vitro efficacy against the currently dominant Omicron COVID-19 sub-variant BA.5, by both of RedHill's novel, oral, host-directed and broad-acting investigational antivirals, once-daily RHB-107 (upamostat) and twice-daily opaganib.
These results build on previously reported data on the inhibition of COVID-19, variants of concern and other viruses, and further support their broad-acting, host-directed mechanisms of action.
The company tested RHB-107 and opaganib using a primary human nasal epithelial cell culture model of Omicron BA.5, which was specifically selected due to the high level of SARS-CoV-2 entry factor expression in these cells. The results show that both RHB-107 and opaganib inhibit Omicron sub-variant BA.5 viral replication, which is indicative of antiviral activity.
The development of both opaganib for hospitalized patients and RHB-107 for non-hospitalized patients is ongoing, including ongoing and planned pandemic preparedness research collaborations with US governmental agencies, pivotal Phase 3 trial design and regulatory clearances, and securing of external non-dilutive funding.
European Markets Close With Mild Losses
Swiss Franc Weakens Against Majors
Pound Falls Against U.S. Dollar, Euro
E.ON Confirms Outlook After Higher Q1 Adj. Earnings
Yen Rises Against Majors
FTSE 100 Flat As Stocks Move In Tight Range
CAC 40 Down 0.66%; Bouygues Rises Sharply On Earnings
